Nicholas J. Vogelzang
Comprehensive Cancer Centers of Nevada · 1,063 works · 69,550 citations · h-index 116
Top works
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
- Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
- Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
- Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
- Hydrocortisone With or Without Mitoxantrone in Men With Hormone-Refractory Prostate Cancer: Results of the Cancer and Leukemia Group B 9182 Study
- Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
- Prognostic Model for Predicting Survival in Men With Hormone-Refractory Metastatic Prostate Cancer
- Impact of Cancer-Related Fatigue on the Lives of Patients: New Findings From the Fatigue Coalition
- Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition.
- Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
- Patterns of care related to age of men with prostate cancer
- Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial
- Raynaud's Phenomenon: A Common Toxicity After Combination Chemotherapy for Testicular Cancer
- Phase II Study of Docetaxel, Estramustine, and Low-Dose Hydrocortisone in Men With Hormone-Refractory Prostate Cancer: A Final Report of CALGB 9780
- Comprehensive Textbook of Genitourinary Oncology
- Treatment of Patients With Metastatic Urothelial Cancer “Unfit” for Cisplatin-Based Chemotherapy
- Initial Hormonal Management of Androgen-Sensitive Metastatic, Recurrent, or Progressive Prostate Cancer: 2007 Update of an American Society of Clinical Oncology Practice Guideline
- Factors Predictive of Survival Among 337 Patients With Mesothelioma Treated Between 1984 and 1994 by the Cancer and Leukemia Group B